Penn Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Penn Capital Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.1M	Buy	298,914 +42,147	+16%	+$4.23M	2.22%	3
2026 Q1	$23.8M	Sell	256,767 -25,151	-9%	-$2.37M	1.84%	1
2025 Q4	$22.3M	Sell	281,918 -26,073	-8%	-$1.87M	1.78%	3
2025 Q3	$22.6M	Sell	307,991 -34,265	-10%	-$2.18M	1.74%	4
2025 Q2	$17.5M	Sell	342,256 -31,263	-8%	-$1.39M	1.51%	17
2025 Q1	$16.9M	Buy	373,519 +95,092	+34%	+$4.48M	1.64%	12
2024 Q4	$11.5M	Sell	278,427 -30,817	-10%	-$1.28M	1.13%	42
2024 Q3	$12.1M	Buy	309,244 +68,093	+28%	+$2.72M	1.11%	42
2024 Q2	$8.26M	Sell	241,151 -4,545	-2%	-$119K	0.78%	62
2024 Q1	$6.18M	Sell	245,696 -32	-0%	-$880	0.55%	71
2023 Q4	$7.26M	Sell	245,728 -242	-0.1%	-$7.32K	0.67%	68
2023 Q3	$7.78M	Buy	245,970 +6,696	+3%	+$183K	0.8%	62
2023 Q2	$6.19M	Buy	+239,274	New	+$6.36M	0.6%	68

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Penn Capital Management's MIRM Position: Q2 2026 in Review

Penn Capital Management increased its Mirum Pharmaceuticals (MIRM) stake by 16% in Q2 2026, buying an estimated $4.23M and bringing the position to 298,914 shares worth $35.1M. The position accounts for 2.22% of the portfolio, ranked #3.

Penn Capital Management first reported a position in MIRM in Q2 2023 and has held it in 13 quarters since. 328 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Penn Capital Management held 298,914 shares of Mirum Pharmaceuticals worth $35.1M as of Q2 2026.
Penn Capital Management bought 42,147 Mirum Pharmaceuticals shares in Q2 2026, an estimated $4.23M.
Mirum Pharmaceuticals made up 2.22% of Penn Capital Management's portfolio in Q2 2026, its #3 holding.
Penn Capital Management first reported a position in Mirum Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
328 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.